Prestige Biologics Secures Contract for Cervical Cancer 9-Valent Vaccine Testing

[Asia Economy Reporter Lee Gwan-joo] Prestige Biologics announced on the 27th that it has signed a contract to outsource the drug safety evaluation for Fosvax's '9-valent human papillomavirus (HPV) vaccine.'

The two companies will conduct safety evaluations over the next three years and plan to establish a close cooperative system related to vaccine development and production.

Fosvax's 9-valent HPV vaccine (PV-001) is a drug for the prevention of cervical cancer. Last month, it received approval for Phase 1 clinical trials from the Ministry of Food and Drug Safety, becoming the first domestic company to do so. Although the 9-valent HPV vaccine prevents over 90% of cervical cancer cases, there is only one commercialized product worldwide, and Korea currently imports all of its supply.

Starting with this contract, Prestige Biologics plans to actively engage in business activities that will realize sales not only in contract manufacturing organization (CMO) but also in contract engineering organization (CEO) sectors.

Yang Jae-young, CEO of Prestige Biologics, stated, “We will fully launch the CDEMO business at our global-level production facility and serve as an advanced base to support the commercialization of biopharmaceutical developers' products by providing the best services.”

This content was produced with the assistance of AI translation services.